Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease--what is the role of anti-TNF antibody?

J Crohns Colitis. 2013 May;7(4):e143-5. doi: 10.1016/j.crohns.2012.06.016. Epub 2012 Jul 19.

Abstract

Biological therapies are supposed to trigger the development of autoimmune diseases. We report a case of a 27-year old woman presenting with drug induced systemic lupus erythematosus (SLE) associated with infliximab therapy. The development of paradoxical inflammation in immune-mediated inflammatory diseases patients treated with anti TNF-α suggests that an unknown inflammatory pathway may be provoked by inhibiting TNF-α. We suppose that in our case a cross reactivity between anti-infliximab antibodies and autoantibodies may lead to the development of TNF-induced immune disease.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Crohn Disease / complications
  • Crohn Disease / drug therapy*
  • Female
  • Humans
  • Infliximab
  • Lupus Erythematosus, Systemic / chemically induced*
  • Lupus Erythematosus, Systemic / complications
  • Lupus Erythematosus, Systemic / diagnosis
  • Lupus Erythematosus, Systemic / immunology

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Infliximab